QT Imaging Holdings Inc (QTI)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$2.70-2.88%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Intact: The reason to own it still holds.
QT Imaging aims to grow revenue to $39 million in 2026. The company raised $10 million to fund growth. New distribution deals expand market reach. Revenue grew from $0.8 million in 2024-Q4 to $8.3 million in 2025-Q4.
QT Imaging is loss-making with negative free cash flow. Earnings estimates have been cut recently. The stock is down nearly 50% from its high. Growth targets may be too optimistic given current losses.
The stock trades about 57% below our $9 fair value, reflecting skepticism on growth and profitability. Our view is more optimistic on revenue growth but cautious on near-term earnings.
Breaks if: failure to raise or maintain capital for growth
Breaks if: no new distribution agreements or loss of existing ones
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has shown volatile management performance, which adds to the uncertainty in its long-term outlook.
The market seems to have priced in a low level of fragility, with QTI being viewed as cheap compared to its peers. However, there is a notable expectations gap, indicating that the market anticipates challenges ahead.
Management has reaffirmed revenue guidance and is on track to achieve approximately $39 million in revenue for 2026. However, the recent financial performance has been weak, and there is a significant probability of missing future estimates.
The thesis hinges on management's ability to meet revenue targets and expand commercial capabilities. Additionally, external factors such as sector performance and economic conditions will play a critical role in determining QTI's trajectory.
The most important moves since the prior daily snapshot.
risk label changed from 'elevated' to 'high'.
Yes, our read has strengthened. The company reported a revenue surge of 116% year-over-year. This strong performance supports its goal of achieving approximately $39 million in revenue for 2026. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue falls below $30 million in FY26
Over the next 1 to 3 years, QTI faces a challenging environment with elevated risks but also potential for growth if management executes well. Not investment advice.